Jun 13 |
Gain Therapeutics Announces Proposed Public Offering
|
May 30 |
Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024
|
May 29 |
Gain Therapeutics: Phase 1 Readout Awaits For Parkinson's Drug With Great Potential
|
May 14 |
Gain Therapeutics GAAP EPS of -$0.22
|
May 14 |
Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update
|
May 3 |
Will Gain Therapeutics, Inc. (GANX) Report Negative Q1 Earnings? What You Should Know
|
Apr 24 |
Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
|
Apr 17 |
Here's Why Gain Therapeutics (GANX) Could be Great Choice for a Bottom Fisher
|
Apr 10 |
Insiders are Piling into These 10 Healthcare Stocks in 2024
|
Apr 10 |
Down -25.88% in 4 Weeks, Here's Why You Should You Buy the Dip in Gain Therapeutics (GANX)
|